A new fixed-dose combination for added blood pressure control: Telmisartan plus hydrochlorothiazide

Journal of International Medical Research

Volumn 30, Issue 4, 2002, Pages 366-379

  Lacourciere Y ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin receptor blocker; Blood pressure control; Combination therapy; Hydrochlorothiazide; Hypertension; Telmisartan

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LOSARTAN; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AWARENESS; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MONOTHERAPY; NEGRO; POTASSIUM DEPLETION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT;

EID: 0036630166     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000203000402     Document Type: Review

References (64)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
3. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data
4. Multiple risk factor intervention trial. Risk factor changes and mortality results
5. Current antihypertensive treatment: Can we do better?
6. Perspectives on systolic hypertension. The Framingham study
7. The natural history of borderline isolated systolic hypertension
8. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
9. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study
10. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction
11. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population
12. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients
13. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial
14. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension
15. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients
16. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
17. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild-to-moderate essential hypertension and type 2 diabetes mellitus
18. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors
19. Primary prevention of the atherosclerotic diseases
20. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
21. Detection and control of high blood pressure in the community: Do we need a wake-up call?
22. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
23. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
24. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data
25. Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management
26. Self-reportedd hypertension treatment practices among primary care physicians: Blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine
27. Compliance with antyhypertensive therapy
28. Clinicians and patients with hypertension: Unsettled issues about compliance
29. Cardiovascular protection and blood pressure reduction: A meta-analysis
30. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
31. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
32. Results of combination anti-hypertensive therapy after failure of each of the components
33. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
34. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
35. A rational approach to the treatment of hypertention in special populations
36. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension
37. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
38. Matrix study of irbesartan with hydrocholorthiazide in mild-to-moderate hyperension
39. Angiotensin converting enzyme inhibitors enhance the anti-hypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects
40. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension
41. Combined enalapril and felodipine extended release (ER) for systemic hypertension
42. Cost effectiveness of combination therapy
43. The role of low-dose combination therapy in the management of hypertension: An alternative approach
44. Combination antihypertensive drugs: Recommendations for use
45. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
46. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
47. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
48. Safe and effective management of hypertension with fixed-dose combination therapy: Focus on losartan plus hydrochlorothiazide
49. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monography
50. A combination of candesartan cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a similar antihypertensive efficacy and is better tolerated than lisinopril/HCTZ, 10/12.5 mg
51. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
52. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension
53. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
54. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker temisartan to amlodipine
55. Once-daily telmisartan compared with enalapril in the treatment of hypertension
56. Dose-finding study of candesartan cilexetil plus hydro-chlorothiazide in patients with mild to moderate hypertension
57. Enalapril: A review of human pharmacology
58. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - A randomized controlled trial
59. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotheraphies
60. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotheraphy
61. Comparison of a fixed-dose combination of telmisartan 40 mg plus hydorchlorothiazide 12.5 mg with telmisartan 40 mg in the control of mild-to-moderate hypertension
62. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension
63. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications
64. Long-term exposure to therapy: Efficacy and safety